Intrinsic value of Prometic Life Sciences Inc. - PLI

Previous Close

$0.76

  Intrinsic Value

$0.05

stock screener

  Rating & Target

str. sell

-94%

Previous close

$0.76

 
Intrinsic value

$0.05

 
Up/down potential

-94%

 
Rating

str. sell

We calculate the intrinsic value of PLI stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  -36.00
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  16
  26
  40
  59
  86
  121
  166
  223
  293
  378
  477
  592
  724
  873
  1,038
  1,221
  1,420
  1,636
  1,868
  2,115
  2,378
  2,656
  2,949
  3,256
  3,577
  3,913
  4,263
  4,628
  5,007
  5,402
  5,812
Variable operating expenses, $m
 
  86
  133
  200
  290
  409
  562
  754
  990
  1,274
  1,609
  1,998
  2,443
  2,945
  3,504
  4,120
  4,793
  5,521
  6,303
  7,139
  8,026
  8,964
  9,952
  10,988
  12,073
  13,206
  14,388
  15,619
  16,899
  18,231
  19,615
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  128
  86
  133
  200
  290
  409
  562
  754
  990
  1,274
  1,609
  1,998
  2,443
  2,945
  3,504
  4,120
  4,793
  5,521
  6,303
  7,139
  8,026
  8,964
  9,952
  10,988
  12,073
  13,206
  14,388
  15,619
  16,899
  18,231
  19,615
Operating income, $m
  -112
  -61
  -94
  -140
  -204
  -288
  -395
  -531
  -697
  -897
  -1,133
  -1,406
  -1,719
  -2,072
  -2,466
  -2,899
  -3,373
  -3,885
  -4,436
  -5,023
  -5,648
  -6,308
  -7,003
  -7,732
  -8,496
  -9,293
  -10,125
  -10,991
  -11,892
  -12,829
  -13,803
EBITDA, $m
  -108
  -51
  -79
  -118
  -171
  -242
  -332
  -446
  -586
  -753
  -952
  -1,182
  -1,445
  -1,742
  -2,072
  -2,436
  -2,834
  -3,265
  -3,727
  -4,221
  -4,746
  -5,301
  -5,885
  -6,498
  -7,140
  -7,810
  -8,509
  -9,236
  -9,994
  -10,781
  -11,599
Interest expense (income), $m
  0
  2
  4
  8
  13
  21
  31
  43
  59
  78
  102
  129
  161
  198
  239
  285
  335
  390
  450
  514
  583
  656
  733
  814
  899
  988
  1,081
  1,178
  1,279
  1,384
  1,494
Earnings before tax, $m
  -117
  -62
  -98
  -148
  -217
  -308
  -426
  -574
  -756
  -975
  -1,234
  -1,535
  -1,880
  -2,270
  -2,705
  -3,184
  -3,708
  -4,275
  -4,886
  -5,538
  -6,231
  -6,964
  -7,736
  -8,546
  -9,395
  -10,282
  -11,206
  -12,169
  -13,171
  -14,213
  -15,296
Tax expense, $m
  -6
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -101
  -62
  -98
  -148
  -217
  -308
  -426
  -574
  -756
  -975
  -1,234
  -1,535
  -1,880
  -2,270
  -2,705
  -3,184
  -3,708
  -4,275
  -4,886
  -5,538
  -6,231
  -6,964
  -7,736
  -8,546
  -9,395
  -10,282
  -11,206
  -12,169
  -13,171
  -14,213
  -15,296

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  39
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  265
  361
  557
  833
  1,209
  1,705
  2,345
  3,147
  4,132
  5,317
  6,716
  8,340
  10,196
  12,290
  14,623
  17,194
  20,001
  23,039
  26,304
  29,791
  33,494
  37,408
  41,530
  45,855
  50,383
  55,113
  60,045
  65,181
  70,524
  76,081
  81,856
Adjusted assets (=assets-cash), $m
  226
  361
  557
  833
  1,209
  1,705
  2,345
  3,147
  4,132
  5,317
  6,716
  8,340
  10,196
  12,290
  14,623
  17,194
  20,001
  23,039
  26,304
  29,791
  33,494
  37,408
  41,530
  45,855
  50,383
  55,113
  60,045
  65,181
  70,524
  76,081
  81,856
Revenue / Adjusted assets
  0.071
  0.072
  0.072
  0.071
  0.071
  0.071
  0.071
  0.071
  0.071
  0.071
  0.071
  0.071
  0.071
  0.071
  0.071
  0.071
  0.071
  0.071
  0.071
  0.071
  0.071
  0.071
  0.071
  0.071
  0.071
  0.071
  0.071
  0.071
  0.071
  0.071
  0.071
Average production assets, $m
  182
  291
  450
  673
  976
  1,377
  1,894
  2,542
  3,337
  4,294
  5,424
  6,736
  8,235
  9,926
  11,810
  13,886
  16,153
  18,607
  21,244
  24,060
  27,050
  30,212
  33,540
  37,034
  40,691
  44,511
  48,494
  52,642
  56,957
  61,445
  66,109
Working capital, $m
  32
  -2
  -2
  -4
  -5
  -8
  -10
  -14
  -18
  -24
  -30
  -37
  -46
  -55
  -65
  -77
  -89
  -103
  -118
  -133
  -150
  -167
  -186
  -205
  -225
  -247
  -269
  -292
  -315
  -340
  -366
Total debt, $m
  49
  119
  229
  384
  595
  874
  1,234
  1,685
  2,238
  2,904
  3,690
  4,603
  5,646
  6,823
  8,134
  9,579
  11,156
  12,864
  14,699
  16,658
  18,739
  20,939
  23,256
  25,687
  28,232
  30,890
  33,661
  36,548
  39,551
  42,673
  45,919
Total liabilities, $m
  133
  203
  313
  468
  679
  958
  1,318
  1,769
  2,322
  2,988
  3,774
  4,687
  5,730
  6,907
  8,218
  9,663
  11,240
  12,948
  14,783
  16,742
  18,823
  21,023
  23,340
  25,771
  28,316
  30,974
  33,745
  36,632
  39,635
  42,757
  46,003
Total equity, $m
  132
  158
  244
  365
  529
  747
  1,027
  1,378
  1,810
  2,329
  2,942
  3,653
  4,466
  5,383
  6,405
  7,531
  8,760
  10,091
  11,521
  13,048
  14,670
  16,385
  18,190
  20,085
  22,068
  24,140
  26,300
  28,549
  30,890
  33,323
  35,853
Total liabilities and equity, $m
  265
  361
  557
  833
  1,208
  1,705
  2,345
  3,147
  4,132
  5,317
  6,716
  8,340
  10,196
  12,290
  14,623
  17,194
  20,000
  23,039
  26,304
  29,790
  33,493
  37,408
  41,530
  45,856
  50,384
  55,114
  60,045
  65,181
  70,525
  76,080
  81,856
Debt-to-equity ratio
  0.371
  0.750
  0.940
  1.050
  1.120
  1.170
  1.200
  1.220
  1.240
  1.250
  1.250
  1.260
  1.260
  1.270
  1.270
  1.270
  1.270
  1.270
  1.280
  1.280
  1.280
  1.280
  1.280
  1.280
  1.280
  1.280
  1.280
  1.280
  1.280
  1.280
  1.280
Adjusted equity ratio
  0.412
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -101
  -62
  -98
  -148
  -217
  -308
  -426
  -574
  -756
  -975
  -1,234
  -1,535
  -1,880
  -2,270
  -2,705
  -3,184
  -3,708
  -4,275
  -4,886
  -5,538
  -6,231
  -6,964
  -7,736
  -8,546
  -9,395
  -10,282
  -11,206
  -12,169
  -13,171
  -14,213
  -15,296
Depreciation, amort., depletion, $m
  4
  10
  15
  22
  33
  46
  63
  85
  111
  143
  181
  225
  274
  331
  394
  463
  538
  620
  708
  802
  902
  1,007
  1,118
  1,234
  1,356
  1,484
  1,616
  1,755
  1,899
  2,048
  2,204
Funds from operations, $m
  -100
  -53
  -83
  -126
  -185
  -263
  -363
  -489
  -645
  -832
  -1,053
  -1,311
  -1,606
  -1,939
  -2,311
  -2,721
  -3,169
  -3,655
  -4,178
  -4,736
  -5,329
  -5,957
  -6,618
  -7,312
  -8,039
  -8,798
  -9,590
  -10,415
  -11,273
  -12,165
  -13,093
Change in working capital, $m
  -2
  -1
  -1
  -1
  -2
  -2
  -3
  -4
  -4
  -5
  -6
  -7
  -8
  -9
  -10
  -12
  -13
  -14
  -15
  -16
  -17
  -18
  -18
  -19
  -20
  -21
  -22
  -23
  -24
  -25
  -26
Cash from operations, $m
  -98
  -52
  -82
  -125
  -183
  -260
  -360
  -486
  -640
  -827
  -1,047
  -1,304
  -1,598
  -1,930
  -2,300
  -2,710
  -3,157
  -3,642
  -4,163
  -4,720
  -5,313
  -5,939
  -6,599
  -7,293
  -8,018
  -8,777
  -9,568
  -10,392
  -11,249
  -12,140
  -13,067
Maintenance CAPEX, $m
  0
  -6
  -10
  -15
  -22
  -33
  -46
  -63
  -85
  -111
  -143
  -181
  -225
  -274
  -331
  -394
  -463
  -538
  -620
  -708
  -802
  -902
  -1,007
  -1,118
  -1,234
  -1,356
  -1,484
  -1,616
  -1,755
  -1,899
  -2,048
New CAPEX, $m
  -16
  -109
  -159
  -223
  -303
  -401
  -516
  -648
  -796
  -957
  -1,130
  -1,311
  -1,499
  -1,691
  -1,884
  -2,076
  -2,267
  -2,454
  -2,637
  -2,816
  -2,991
  -3,161
  -3,329
  -3,494
  -3,657
  -3,820
  -3,983
  -4,148
  -4,316
  -4,487
  -4,664
Cash from investing activities, $m
  10
  -115
  -169
  -238
  -325
  -434
  -562
  -711
  -881
  -1,068
  -1,273
  -1,492
  -1,724
  -1,965
  -2,215
  -2,470
  -2,730
  -2,992
  -3,257
  -3,524
  -3,793
  -4,063
  -4,336
  -4,612
  -4,891
  -5,176
  -5,467
  -5,764
  -6,071
  -6,386
  -6,712
Free cash flow, $m
  -88
  -167
  -251
  -363
  -509
  -694
  -922
  -1,197
  -1,521
  -1,895
  -2,320
  -2,796
  -3,322
  -3,895
  -4,515
  -5,180
  -5,887
  -6,634
  -7,420
  -8,244
  -9,105
  -10,002
  -10,935
  -11,904
  -12,910
  -13,953
  -15,034
  -16,156
  -17,319
  -18,526
  -19,779
Issuance/(repayment) of debt, $m
  30
  76
  110
  155
  211
  279
  359
  451
  554
  666
  786
  913
  1,043
  1,177
  1,311
  1,445
  1,577
  1,708
  1,835
  1,960
  2,081
  2,200
  2,316
  2,431
  2,545
  2,658
  2,772
  2,886
  3,003
  3,123
  3,246
Issuance/(repurchase) of shares, $m
  61
  121
  184
  269
  382
  526
  706
  925
  1,187
  1,494
  1,847
  2,247
  2,694
  3,187
  3,726
  4,310
  4,937
  5,606
  6,316
  7,065
  7,853
  8,678
  9,541
  10,441
  11,378
  12,353
  13,366
  14,419
  15,512
  16,647
  17,826
Cash from financing (excl. dividends), $m  
  87
  197
  294
  424
  593
  805
  1,065
  1,376
  1,741
  2,160
  2,633
  3,160
  3,737
  4,364
  5,037
  5,755
  6,514
  7,314
  8,151
  9,025
  9,934
  10,878
  11,857
  12,872
  13,923
  15,011
  16,138
  17,305
  18,515
  19,770
  21,072
Total cash flow (excl. dividends), $m
  -1
  30
  44
  62
  84
  111
  143
  180
  220
  265
  313
  363
  415
  469
  522
  575
  628
  680
  731
  780
  829
  876
  922
  968
  1,013
  1,058
  1,104
  1,149
  1,196
  1,243
  1,292
Retained Cash Flow (-), $m
  -19
  -121
  -184
  -269
  -382
  -526
  -706
  -925
  -1,187
  -1,494
  -1,847
  -2,247
  -2,694
  -3,187
  -3,726
  -4,310
  -4,937
  -5,606
  -6,316
  -7,065
  -7,853
  -8,678
  -9,541
  -10,441
  -11,378
  -12,353
  -13,366
  -14,419
  -15,512
  -16,647
  -17,826
Prev. year cash balance distribution, $m
 
  33
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  -59
  -140
  -208
  -298
  -415
  -563
  -746
  -967
  -1,229
  -1,534
  -1,883
  -2,278
  -2,719
  -3,204
  -3,735
  -4,309
  -4,926
  -5,585
  -6,285
  -7,024
  -7,802
  -8,619
  -9,473
  -10,365
  -11,295
  -12,263
  -13,270
  -14,316
  -15,404
  -16,534
Discount rate, %
 
  6.20
  6.51
  6.84
  7.18
  7.54
  7.91
  8.31
  8.72
  9.16
  9.62
  10.10
  10.60
  11.13
  11.69
  12.28
  12.89
  13.53
  14.21
  14.92
  15.67
  16.45
  17.27
  18.14
  19.04
  20.00
  21.00
  22.05
  23.15
  24.30
  25.52
PV of cash for distribution, $m
 
  -55
  -124
  -170
  -226
  -288
  -356
  -427
  -495
  -558
  -612
  -654
  -680
  -689
  -682
  -658
  -619
  -569
  -511
  -447
  -382
  -319
  -259
  -205
  -158
  -119
  -86
  -61
  -42
  -28
  -18
Current shareholders' claim on cash, %
  100
  77.0
  59.9
  47.2
  37.5
  30.2
  24.5
  20.1
  16.6
  13.8
  11.6
  9.8
  8.3
  7.0
  6.0
  5.2
  4.5
  3.9
  3.3
  2.9
  2.5
  2.2
  1.9
  1.7
  1.5
  1.3
  1.2
  1.0
  0.9
  0.8
  0.7

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs. ProMetic is also developing its own small molecule therapeutic products targeting unmet medical needs in the field of fibrosis, autoimmune disease/inflammation and cancer. It has research and development facilities in the United Kingdom, the United States and Canada; manufacturing facilities in the Isle of Man and Canada, and business development activities in the United States, Europe and Asia.

FINANCIAL RATIOS  of  Prometic Life Sciences Inc. (PLI)

Valuation Ratios
P/E Ratio -4.7
Price to Sales 29.6
Price to Book 3.6
Price to Tangible Book
Price to Cash Flow -4.8
Price to Free Cash Flow -4.2
Growth Rates
Sales Growth Rate -36%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 128.6%
Cap. Spend. - 3 Yr. Gr. Rate 14.9%
Financial Strength
Quick Ratio 7
Current Ratio 0
LT Debt to Equity 32.6%
Total Debt to Equity 37.1%
Interest Coverage 0
Management Effectiveness
Return On Assets -42.1%
Ret/ On Assets - 3 Yr. Avg. -20.6%
Return On Total Capital -63.7%
Ret/ On T. Cap. - 3 Yr. Avg. -32.8%
Return On Equity -82.4%
Return On Equity - 3 Yr. Avg. -41.6%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 62.5%
Gross Margin - 3 Yr. Avg. 65.4%
EBITDA Margin -706.3%
EBITDA Margin - 3 Yr. Avg. -312.6%
Operating Margin -700%
Oper. Margin - 3 Yr. Avg. -336.6%
Pre-Tax Margin -731.3%
Pre-Tax Margin - 3 Yr. Avg. -326.4%
Net Profit Margin -631.3%
Net Profit Margin - 3 Yr. Avg. -269.7%
Effective Tax Rate 5.1%
Eff/ Tax Rate - 3 Yr. Avg. 4.4%
Payout Ratio 0%

PLI stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the PLI stock intrinsic value calculation we used $16 million for the last fiscal year's total revenue generated by Prometic Life Sciences Inc.. The default revenue input number comes from 2016 income statement of Prometic Life Sciences Inc.. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our PLI stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 6.2%, whose default value for PLI is calculated based on our internal credit rating of Prometic Life Sciences Inc., is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Prometic Life Sciences Inc..
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of PLI stock the variable cost ratio is equal to 337.5%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for PLI stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Prometic Life Sciences Inc..

Corporate tax rate of 27% is the nominal tax rate for Prometic Life Sciences Inc.. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the PLI stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for PLI are equal to 1137.5%.

Life of production assets of 45.5 years is the average useful life of capital assets used in Prometic Life Sciences Inc. operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for PLI is equal to -6.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $132 million for Prometic Life Sciences Inc. - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 710.362 million for Prometic Life Sciences Inc. is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Prometic Life Sciences Inc. at the current share price and the inputted number of shares is $0.5 billion.

RELATED COMPANIES Price Int.Val. Rating
VRX Valeant Pharma 30.11 24.60  hold
Financial statements of PLI
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.